Wednesday, February 10, 2010, 9:03pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Halozyme Therapeutics, Inc. (HALO)

At 5:00AM SGT: 5.49 USD   0.00 (0.00%)  
 MORE ON HALO 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Halozyme Therapeutics, Inc. (NGM:HALO) Delayed quote dataEdit
Last Trade:5.49 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:5.49
Open:N/A
Bid:0.01 x 200
Ask:2,000.00 x 200
1y Target Est:11.33
Day's Range:N/A - N/A
52wk Range:3.93 - 8.09
Volume:0
Avg Vol (3m):391,400
Market Cap:503.14M
P/E (ttm):N/A
EPS (ttm):-0.74
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add HALO to Portfolio   Download Data

 HEADLINES 
•HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Tue 9:30pm)
•[video] Trading Smallcap Biotech
at TheStreet.com (Mon, Feb 1)
•Halozyme signs research contract with BioAtla
AP (Tue, Jan 19)
•Halozyme Announces Research Alliance with BioAtla for Conditionally Active Biologics
Business Wire (Tue, Jan 19)
•HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Mon, Jan 11)
•Halozyme to Present at J.P. Morgan Healthcare Conference on January 13
Business Wire (Wed, Jan 6)
•Halozyme, Beazer: Early Volume Plays
at TheStreet.com (Wed, Jan 6)
•HALOZYME THERAPEUTICS INC Financials
EDGAR Online Financials (Wed, Nov 11)
•Halozyme Earnings Call scheduled for 11:00 am ET today
CCBN (Sat, Nov 7)
•HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Fri, Nov 6)
More Headlines for HALO...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.70
EPS Est (in 2 years) (Dec-10) :-0.64
Avg Rec (current)*:1.8
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices